Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05513742Phase 2Completed

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Role: lead

NCT07419841Phase 1Recruiting

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Role: lead

NCT05506943Phase 2Completed

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Role: lead

NCT06150664Phase 1Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Role: lead

NCT03881488Phase 1Completed

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Role: lead

NCT07392957Phase 1Not Yet Recruiting

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Role: collaborator

NCT04492033Phase 1Terminated

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Role: collaborator

All 7 trials loaded